Editing GSK plc (section)

=== Operation in Russia ===
Following Russia's invasion of Ukraine in 2022, GlaxoSmithKline (GSK) was criticized for continuing its operations in Russia, despite the ongoing conflict and international sanctions. Although GSK suspended clinical trials, advertising, and promotion in Russia, the company has maintained its supply of essential medicines, vaccines, and medical equipment, with proceeds reportedly directed towards humanitarian aid. Critics argue that GSK's decision to continue exporting products—resulting in increased sales and profit volumes in 2022 compared to 2021—undermines the intended impact of sanctions, raising ethical concerns.<ref>{{Cite web |last=Dunn |first=Catherine |date=2022-03-11 |title=U.S. pharma companies are staying in Russia as other industries exit |url=https://www.inquirer.com/business/big-pharma-russia-ukraine-merck-johnson-and-johnson-pfizer-gsk-20220311.html |access-date=2024-12-05 |website=www.inquirer.com |language=en}}</ref><ref>{{cite news |date=2022-03-17 |title=GSK to supply essential medicines in Russia, halts clinical trials |url=https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-supply-essential-medicines-russia-halts-clinical-trials-2022-03-17/ |access-date=2024-12-05 |publisher=Reuters}}</ref><ref>{{Cite news |last=Kollewe |first=Julia |date=2022-03-17 |title=GlaxoSmithKline says it will not start any new clinical trials in Russia |url=https://www.theguardian.com/business/2022/mar/17/glaxosmithkline-says-it-will-not-start-any-new-clinical-trials-in-russia |access-date=2024-12-05 |work=The Guardian |language=en-GB |issn=0261-3077}}</ref>